Our first-in-class structural chemoproteomics platform (CPP) reveals protein conformational changes directly in complex biological systems in vivo — revealing protein misfolding at its earliest stages before organ damage occurs in diseases like Alzheimer’s and Amyloidosis. Precise drug target identification, and quantitative insights into drug engagement and safety on a proteome-wide scale open entirely new possibilities for de-risking drug development.

3D BioAnalytiX Recognized as Hello Tomorrow Deep Tech Pioneer and Connect Cool Company 2026

3D BioAnalytiX has been selected as both a Hello Tomorrow Deep Tech Pioneer 2026 and a Connect Cool Company 2026, positioning the company among leading deep tech innovators globally and venture-ready, high-growth startups within Southern California’s ecosystem, following a highly competitive selection from over 4,800 companies worldwide and more than 150 regional applicants. These distinctions come at a time of accelerating momentum for 3D BioAnalytiX as it advances its structural chemoproteomics platform for early disease detection and more de-risked drug development. We look forward to connecting with global investors and partners at the Hello Tomorrow Global Summit in Amsterdam June 11-12th, 2026 and through Connect’s network in San Diego. Learn more by clicking on each icon.